To the Editor:
Hepcidin plays a central role in iron homeostasis and contributes to the pathogenesis of several disorders. Consequently, development of a clear understanding of hepcidin regulation in various pathophysiological conditions has been the subject of intensive research. Technical limitations, however, have limited the wide availability of assays for measuring this iron-regulatory hormone in human serum. Recently, Troutt et al. developed a specific and robust sandwich immunoassay for hepcidin-25 and measured it in the serum of healthy volunteers. They reported diurnal variation in its concentrations in the circulation (1 ) . In particular, the authors demonstrated that hepcidin-25 concentrations were significantly increased after 3 days of fasting, an intriguing result considering the hyposideremic effect of hepcidin. The authors hypothesized that this increase in hepcidin could be caused by suppressed erythropoiesis to maintain tissue iron concentrations.
To investigate the molecular mechanisms responsible for hepcidin regulation by fasting, we fasted C57BL/6J mice for 24 h and then separated them into 2 groups. The first group was fasted for an additional 12-h period ("fasted" conditions); the second group was refed during the 12-h period with a highcarbohydrate diet ("refed" conditions). Interestingly, mouse hepcidin antimicrobial peptide 1 (hepcidin1) 1 mRNA concentrations were increased 4.2-fold with fasting [mean (SD) relative concentration, 1 (0.1) for the refed mice (n ϭ 6) vs 4.2 (0.1) for the fasted mice (n ϭ 6); P Ͻ 0.0001], with a significant 25% decrease of plasma iron. These findings confirm the results of Troutt et al. and suggest that an increase in hepcidin-25 in human serum most likely reflects the direct upregulation of HAMP 2 (hepcidin antimicrobial peptide) gene expression in response to fasting.
To determine whether this regulation could be explained by systemic and/or cell autonomous pathways, we studied mouse Hamp1 (hepcidin antimicrobial peptide 1) gene expression in isolated hepatocytes maintained under culture conditions that mimic the fasting/ gluconeogenic state. To achieve these conditions, we deprived isolated mouse hepatocytes of serum for 16 h and then treated them for 8 h with dibutyryl-cAMP (to mimic the effect of increased glucagon when blood glucose concentrations are low). These gluconeogenic conditions per se induced Hamp1 gene expression 2-fold [mean relative concentration, 1 (0.1) for controls (n ϭ 3) vs 2.1 (0.1) in dibutyryl-cAMP-treated hepatocytes (n ϭ 3); P Ͻ 0.0001]. Given the ability of peroxisome proliferator-activated receptor ␥ coactivator 1␣ (PGC-1␣) to activate components of the fasting response in the liver, we investigated the role of this transcriptional factor by infecting mouse primary hepatocytes for 24 h at a multiplicity of infection of 25 with adenovirus producing either PGC-1␣ or green fluorescent protein as a control (2 ) . Forced production of PGC-1␣ increased Hamp1 gene expression 2-fold [mean relative concentration, 1 (0.1) in control hepatocytes infected with green fluorescent protein-producing adenovirus (n ϭ 3) vs 2.0 (0.1) in hepatocytes infected with PGC-1␣-producing adenovirus (n ϭ 3); P Ͻ 0.0001]. Also increased were glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, 2 well-known PGC-1␣ targets involved in gluconeogenesis. In addition, we found a significant correlation between relative concentrations of PGC-1␣ and hepcidin1 in the livers of fasted/refed animals (Fig. 1 ). Measurements were made by quantitative reverse-transcription PCR of RNA isolated from the liver of fasted mice (n ϭ 6) and refed mice (n ϭ 6).
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Letters to the Editor PGC-1␣ has recently emerged as an important regulator of several liver functions. In the hepatic response to fasting, PGC-1␣ has been shown to coordinate the induction of gluconeogenic enzymes by coactivating such liver-enriched transcription factors as hepatocyte nuclear factor 4␣ (HNF4␣) and forkhead box O1 protein (FOXO1), as well as the glucocorticoid receptor (3 ). Whether these regulators are involved in the control of hepcidin gene expression by fasting awaits further investigations.
Ourresultssuggestthatactivation of the expression of the gene encoding hepcidin during fasting could be due not only to systemic regulation (such as decreased erythropoiesis, as suggested by Troutt et al.) but also to PGC-1␣-dependent cell autonomous activation. This increase of hepcidin1 by fasting can explain the results of Conrad et al. (4 ), who were the first to show that 5 days of starvation in rats led to decreased absorption of iron administered orally. This observed increase in hepcidin with fasting also is in agreement with the recent report by Papillard-Marechal et al. (5 ) , who found increased serum hepcidin concentrations in patients with anorexia nervosa, the increased hepcidin concentrations in their study being independent of inflammation and iron overload. Clarke et al. conclude that serum homocysteine does not cause ischemic heart disease (IHD) (1 ), an assessment they based on 19 new studies that showed no increased IHD risk in individuals with the MTHFR [methylenetetrahydrofolate reductase (NAD(P)H)] polymorphism, compared with those without. In excluding results from 86 earlier publications that collectively did show an increased risk, they claimed that the reports of increased risk were due to publication bias (1 ) . The 19 new studies were incorrectly described as "unpublished," the implication being that they caused the publication bias (preferential reporting of small studies with positive results over small studies with negative results), but they were new analyses on previously stored samples or data.
MTHFR polymorphism studies are used to investigate whether homocysteine and IHD are causally linked, because moderately increased homocysteine concentrations can be caused by, in certain environments (e.g., low folate), the C-to-T mutation in the MTHFR gene. The study of IHD risk in people with the mutation (TT) and without it (CC) provides a natural randomized experiment of the relationship of homocysteine to IHD (2 ) .
We performed 2 analyses to address the issue: (a) an overall metaanalysis of the 19 new studies and the 86 earlier publications to determine whether any effect was apparent when all available data were used, and (b) a "doseresponse analysis" comparing IHD risk (TT vs CC) according to the differences between TT and CC individuals with respect to homocysteine concentration in each study.
The metaanalysis of the 107 MTHFR studies (86 previous publications reporting on 88 studies (1 ) and the 19 new ones) that compared IHD risk in TT and CC individuals (76 792 individuals with IHD and 109 818 unaffected con-
